Experts delve into practical aspects of using elacestrant in later-line treatment of patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer, including testing for ESR1 mutations, evaluating efficacy, and monitoring for toxicity.
Experts discuss the necessity of ESR1 mutation testing when considering treatment with elacestrant in patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer and discuss unmet needs in this patient population. They also describe options for mutation and resistance marker testing to guide treatment selection.
Experts explore the efficacy and safety profiles of elacestrant, an oral Selective Estrogen Receptor Degrader (SERD), and other options for endocrine therapy. The panelists also discuss clinical trial insights, progression-free survival rates, and tolerability, highlighting outcomes and advantages in metastatic breast cancer treatment.